trans-N,N’-dimethylcyclohexane-1,2-diamine | CAS:67579-81-1

We serve trans-N,N’-dimethylcyclohexane-1,2-diamine CAS:67579-81-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
trans-N,N'-dimethylcyclohexane-1,2-diamine

CAS No: 67579-81-1
Product Name: trans-N,N'-dimethylcyclohexane-1,2-diamine
Other Name:
trans-N,N'-dimethylcyclohexane-1,2-diamine
N,N'-Dimethyl-1,2-cyclohexanediamine
N,N'-Dimethylcyclohexane-1,2-diamine
(1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine
 
Density: 0.9±0.1 g/cm3
Boiling Point: 186.8±8.0 °C at 760 mmHg
Melting Point: 4℃
Molecular Formula: C8H18N2
Molecular Weight: 142.242
Flash Point: 60.2±10.2 °C
Exact Mass: 142.147003
PSA: 24.06000
LogP: 0.35
Vapour Pressure: 0.7±0.4 mmHg at 25°C
Index of Refraction: 1.469
Storage condition: Refrigerator
 
Specification
Appearance: Colorless or light yellow liquid
Purity (GC): ≥99.0%
Water(Karl-Fisher): ≤1.0%
Other impurities: ≤1.0%
Assay: ≥98.0%
 
Application
Intermediates of Oxaliplatin CAS: 61825-94-3.
Be used as pharmaceutical intermediate.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like trans-N,N’-dimethylcyclohexane-1,2-diamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(1R,2R)-N1,N2-dimethylcyclohexane-1,2-diamine Use and application,trans-N,N’-dimethylcyclohexane-1,2-diamine technical grade,usp/ep/jp grade.


Related News: The measure starts on February 4, according to South Korean Prime Minister Chung Sye-kyun.2-Bromotoluene manufacturer These include: high-barrier generic drug substances and commonly used generic drug substances.Methyl 3-aminocrotonate supplier Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.dimethyl-bis[[methyl(diphenyl)silyl]oxy]silane vendor “Out of an abundance of caution and based on the latest advice from leading health experts, we’re closing all our corporate offices, stores and contact centers in mainland China through February 9.”This leads to low numbers of one or more types of circulating blood cells, and to the need for blood transfusions. In MDS, some of the cells in the bone marrow are abnormal (dysplastic) and may have genetic abnormalities associated with them.